The proceeds from the financing will fund Latus Bio’s operations through key clinical milestones.

The move positions Anthropic in a $100B+ drug discovery market that’s ripe for disruption, blending frontier models with wet-lab integration.

Austin,TX , Sensor Bio, the continuous biometric signal infrastructure platform built for clinical, enterprise, and AI ...

Innovative “virus-like particle” platform technology significantly expands the agricultural application potential of ...

Introducing a new RNA-seq platform for intracellular multimodal profiling that could transform cancer research and ...

Samsung is proceeding with an investment in Averr BioTechnology (Averr Bio), a U.S.-based biotech company specializing in gene-editing technology. The move aims to explore high-growth new business ...

Sonomind SAS raised €20 million (US$23 million) in a series A funding round for its ultrasound-based neuromodulation ...

Materials company UPM (Helsinki, Finland; today announced that it has reached an agreement with Avantium N.V. (Amsterdam, ...